NuVasive To Expands Global Presence, Pediatric Portfolio With Ellipse Buy
This article was originally published in Clinica
Executive Summary
On Jan. 5, NuVasive said it agreed to buy Ellipse in a deal that is expected to be complete by the end of February. NuVasive will pay an additional $30 million in 2017 if Ellipse's portfolio meets certain revenue targets.
You may also be interested in...
Earnings Winners And Losers: BSX, BCR, NUVA, NVCR
Several big names in medtech announced their second-quarter sales and earnings in late July and early August. Here are some of the companies that impressed investors and others that raised some doubts.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.